Login
Navigate Fool.com
Will ACOR beat
the market?
Community Rating: 3 Stars: Appealing

34.62 -0.72 (-2.04%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $35.19
Previous Close $35.34
Daily Range $34.31 - $35.49
52-Week Range $27.51 - $40.87
Market Cap $1.4B
P/E Ratio 90.62
Dividend (Yield) $0.00 (0.0%)
Volume 365,300
Average Daily Volume 477,054
Current FY EPS $0.42

How do you think ACOR
will perform against the market?

Top ACOR Bull/Bear Pitches

 

zzlangerhans (< 20)
Submitted October 14, 2010

Acorda seems to be wandering in a sine wave pattern as alternatively optimistic and pessimistic views of the commercial potential of their multiple sclerosis drug Ampyra. Ampyra is far from a proven w … More

0 Replies Reply Report this Post
 

Hogty (< 20)
Submitted September 1, 2009

Overvalued. If you want in on the future of CNS research and production invest in a broader, safer buy like STEM. They will benefit from the production and storage regardless of who comes up with the … More

1 Replies Reply Report this Post

News & Commentary

Acorda Therapeutics, The Medicines Co. and Shire Plc Could Be Big Movers in Healthcare Today

Today's movers in healthcare and biotechnology.

MannKind Doubles on FDA News, Could Drive Short Covering in Biotech Sector

After a big slump, biotech is having a great week.

Sector Update: Healthcare

Sector Update: Healthcare Shares Fairly Flat; Acorda Q4 Earnings Top Street View

Cowen Top Biotech Stocks to Buy for 2014 With Huge Upside

Jazz Pharmaceuticals Isn't Tired of Spending Money

Jazz just made another deal to strengthen its specialty drug franchise. Here's what you need to know.

3 Stocks to Get on Your Watchlist

A rapidly growing Bakken-based oil producer, a possible biotech buyout candidate, and a potentially overvalued paper products company are this week's must-watch stocks.

Acorda Receives Five Awards, Including PM360 Trailblazer Award as Best Specialty Pharma/Biotechnolog

Biotech Stocks Continue Recent Downtrend; Ariad Tumbles to Lowest Price in Nearly Three Years

Acorda Therapeutics Gets a New CFO

Michael Rogers is tapped to head the company's finance team.

See More ACOR News...

Sector

Healthcare

Industry

Drugs

Acorda Therapeutics, Inc. (ACOR) Description

A commercial-stage biopharmaceutical company dedicated to the identification, development & commercialization of novel therapies that improve neurological function in people with multiple sclerosis, spinal cord injury and other disorders of the CNS. Website: http://www.acorda.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks